CO-PROMETHEUS-MATERIALS
12.1.2023 14:01:40 CET | Business Wire | Press release
Prometheus Materials, a leader in sustainable building materials, today announced the appointment of Vishaan Chakrabarti, FAIA FRAIC, to its Board of Directors. Chakrabarti joins a dedicated leadership team working to harness Prometheus Materials’ technology to accelerate the world’s transition to a carbon-negative future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230112005190/en/
Vishaan Chakrabarti, FAIA FRAIC – Founder and Creative Director of Practice for Architecture and Urbanism (PAU) – joins the Prometheus Materials Board of Directors. (Photo: Business Wire)
This Board addition comes on the heels of multiple company milestones. In June 2022, Prometheus Materials announced its $8 Million Series A Funding Round led by Paris-based VC firm Sofinnova Partners, with participation by the Microsoft Climate Innovation Fund, Skidmore, Owings & Merrill (SOM), GAF, and The Autodesk Foundation. In July 2022, Prometheus Materials and SOM announced a partnership to ultimately develop zero-carbon building materials.
“We are thrilled to welcome Vishaan to our board,” said Loren Burnett, President and CEO of Prometheus Materials. “Vishaan has unique expertise to help guide the company through new levels of growth – conducting key advocacy work in the market at-large to promote sustainable legislation, helping to drive critical industry connections, and addressing market awareness and acceptance around the benefits of sustainable building materials.”
Chakrabarti brings a wealth of experience to his new role, in which he has acutely focused on sustainable design. He is the Founder and Creative Director of Practice for Architecture & Urbanism (PAU), a design firm dedicated to lasting architecture and human urbanism to advance healthy cities. Previously, he served as Director of Planning for Manhattan, assisting in the reconstruction of the new World Trade Center and the design of New York City’s High Line and 7 Line expansion, among other projects. He also served as Dean at the University of California - Berkeley College of Environmental Design, and has given main stage TED Talks on sustainability in architecture and urban design.
“Joining Prometheus Materials’ board feels like a natural extension of the mission of my life’s work,” said Chakrabarti. “There will be an avalanche of growth in the demand for sustainable building materials in the coming years and Prometheus Materials’ technology is vital in addressing a key polluting sector. Concrete is one of the world’s primary building materials and I’m honored to work with this team to help change the status quo of urban design through sustainable materials.”
Cement production accounts for 8% of annual CO2 emissions and consumes 9% of annual industrial water production on a global basis. In contrast to traditional portland-based cement, the production of Prometheus Materials' microalgae-based building materials emits little-to-no CO2 and recycles 95% of the water used.
About Prometheus Materials
Prometheus Materials provides sustainable building materials that accelerate the world’s transition to a carbon-negative future. Inspired by biological processes found in nature, the company's process uses microalgae to produce a bio-cement that offers an alternative to carbon-intensive portland cement. When mixed with aggregate, this bio-cement forms an ultra low-carbon bio-concrete with mechanical, physical, and thermal properties that rival those of portland cement-based concrete. Learn more about how the company enables the decarbonization of the construction industry at prometheusmaterials.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005190/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
